Welcome, everyone, to the Jefferies Global Healthcare Conference in London. My name is Young Li, one of the med tech analysts on the team. Really pleased to be joined by management from TransMedics. We have the founder, President, and CEO, Waleed Hassanein, and also the recently appointed CFO, Fernando Araujo. Gentlemen, welcome, and thanks for coming to our conference.
Thank you, Young. We appreciate the invite. We're looking forward to it.
All right, great. Why don't we start off high level? I mean, your business is a pretty unique business in the organ transplant industry. You're the leader in livers and hearts, and then you have a very differentiated technology portfolio as well as business model. From your perspective, how defensive is the business model? Because we hear about competitors quite frequently. How real are the competitive threats?
That's an excellent question, Young. I think, as I've stated publicly before, transplant is becoming a crowded marketplace. We're very, very proud of that because TransMedics created this focus on organ transplantation. We think this is a good renaissance for the entire field. However, we also are very confident that we built a very defensible moat that is very, very difficult to replicate, very expensive to replicate, and it takes a long time to replicate. That's the multi-layer of the best technology in the field, surrounded with a very, very large NOP network on a national basis, vertical integration of transplant logistics, digitization of the transplant ecosystem, and more recently, offering donor and recipient coordination for major transplant programs. So, we've proven the model, we've proven the profitability of the model, the operations of the model, and we're now expanding that model into Europe.
We feel pretty confident in our ability to defend that business in face of technology. We are also not standing still. We are investing in a very, very deep pipeline of product innovation, service innovation, digital transformation to continue to keep ahead of the curve and ahead of the pace and drive innovation in the field.
Mm-hmm. All right, great. I guess the recent results were really strong. It was the strongest quarter ever, even if you exclude some of the PAD Aviation revenue. You were able to grow sequentially in a typically pretty tough seasonal 3Q. That hasn't happened over the past two years. I guess, what drove this really strong performance in that quarter, even though donor volumes were down like 6% in that quarter?
I think, Young, as I stated publicly, it's execution, it's the pipeline, primarily ENHANCE Part A was a major catalyst. It's our liver continuing to deliver the best results in the field. It's our NOP service. It's just the expansion of our service program into donor and recipient coordination. Europe generated significantly higher quarter. I would say the entire business really delivered Q3 in a good pace, and we expect that cadence to continue to go forward.
All right, great. When we do KOL checks, we don't get nearly as much pushback on the clinical utility and benefits of OCS. We hear a lot more sort of on the economic side, the higher costs of the products and services. How do your account reps or clinical reps handle those type of conversations, or what type of economic or clinical data do you cite to sort of push back on that?
I think our team get less of those economics pushback because you guys are talking to either generalist or few of the transplant program. Listen, the fundamental thing for TransMedics is we know for a fact we're delivering significant clinical value. For that, there is a premium pricing that has to be involved. We think the huge economic efficiency that we deliver through our NOP network, through our vertical integration of logistics, it's something that surgeon check or the field check doesn't really factor in. Our team knows all those details. For example, I give you one example. We're the only organ preservation technology company that don't charge a dime if the organ is not transplanted after it's being an OCS. Every other technology in the field, any of the competition, they charge full price.
These are the economic things that our team knows how to articulate with the center. Again, you don't need to listen to me describing that. Look at our print, and if the economics are really something that is a challenge for adoption, we wouldn't be able to generate the momentum we're generating in the business today.
Mm-hmm. Got it. I guess, are there still major U.S. transplant programs that don't use TransMedics much, or at all? What's holding them back, and what can you do to eventually convert them?
I think, listen, we're happy with where we are, but we obviously have higher aspiration, and we will continue to drive towards deeper adoption within existing transplant centers and expanding to new centers. I think every major transplant program is familiar with OCS, familiar with TransMedics, familiar with NOP, except for very, very few kind of single-digit number accounts. Again, our team is doing a good job in targeting these accounts. Some of these accounts we have to wait on and be patient because, again, we have a lot to focus on, and one account is not going to be the make or break for TransMedics. We're also expanding into Europe, so again, the team is doing a great job. We're going deeper into existing accounts, we're opening up new accounts, but we have to let the process take its time. We can't force it.
All right, got it. I guess a unique capability that you guys have is scheduled liver transplants. What percentage of TransMedics livers are done that way currently? Are surgeons able to perform two liver transplants in a day using your tech?
Absolutely. Two or more. I would say more than 80% of our livers are done in morning hour transplant. It is one of our most important value proposition that drove adoption in liver transplantation. We designed ENHANCE and DENOVO to give us the ability to prove that capabilities in heart and lung transplantation as well. Yes, many centers are doing more than one liver a day because of that capabilities of OCS, and really NOP, and having the team dedicated to managing the organ while our team managing the organ while the surgeon is doing another transplant case.
All right. There is a lot of positive trial updates and progress in the last quarter. The heart ENHANCE Part A trial that completed enrollment, 175 patients in September. In October, the FDA approved the continued access protocol to enroll an additional 90 patients. What are the drivers and the significance behind that decision, and how does it help approvals?
I think, one, it is twofold. For ENHANCE Part A, the significance is we enrolled a trial that we were counting to enroll over 12- 18 months in seven months. We enrolled 175 patients in roughly speaking seven months, despite some headwind that we experienced in the beginning of enrollment of this trial. So that is huge for us. Also, we know for a fact that we were able to make gain market share in heart transplant in Q2 and Q3 because of that ENHANCE Part A study. The significance of the CAP is this is not going to go away, meaning this momentum we saw in Q3 is not going to go away, and the FDA was able to, based on the strength of the results they reviewed, or interim results they reviewed, they gave us access to an additional 90 patients.
We should expect to see that same level of momentum in that market segment that we currently have an indication for. What excites us is that FDA also, in parallel, gave us finally the approval for the IDEs to start ENHANCE Part B and DENOVO Lung, including CHOPS as the control arm. For us, that is a humongous catalyst for 2027. It gives us access to 600 hearts and 450 lungs that we today don't have access for in the U.S. We have the OCS and CHOPS involved in the trial. For us, that's very, very meaningful and really a significant catalyst for 2027 for TransMedics.
Mm-hmm. Yeah. It definitely opens up another indication that you don't currently have today. I guess for the Part B trial, what's your base case assumption for the pace of enrollment? Should it be materially faster than Part A? Would it sort of be slow initially before it starts to ramp?
Yeah. Yeah, and that's a very important question. We always start with saying 12- 18 months is the baseline, and then we let the pace of enrollment kind of allow us to update that timeline. We will always be conservative in the beginning until we see the pace of enrollment in Q1 and Q2, we'll maintain that 12 months to 18 months horizon to start.
Okay, got it. I guess for the DENOVO Lung side, what is the pace of enrollment there, especially given that your lung franchise has been a lot slower to ramp?
Yeah. I think, again, both ENHANCE Part B and DENOVO are at the same stage. They are very early. They haven't started enrollment yet. We expect that to start in early Q1. So we will be watching both programs together. Again, this is one of the reasons why we are very excited about 2027, because we are tackling heart and lung, not just heart, or not just lung. It is really going to be an exciting year, at least in our view. We will be watching very carefully the first half of the year how these two programs will progress. But until they start, we will always maintain the 12- 18 months horizon for enrollment.
All right, got it. You guys are very focused on the European market. You are preparing to launch NOP in Italy, Netherlands, and Belgium in the first half of next year. What countries are next on the list? What is the reimbursement and approval cadence for these countries?
Yeah. I think from an approval standpoint, let's start with the easy stuff first. Approval, we are approved to operate in Europe for many, many years. We have not a small franchise in Europe across the heart market segment. The plan is to launch NOP and expand that segment from heart to lung to liver. So the plan is to start in Italy. Italy is a very important country for us, not only for the rollout of NOP in Europe, but also for the aviation. We won our first tender in Emilia-Romagna in Q3. We are very excited about this. We are actively engaged in several other tenders in Italy, and we feel bullish about that angle. As far as reimbursement is concerned, we don't initiate a discussion in a geography that we don't have reimbursement in. So it starts with reimbursement.
The plan is to expand beyond the Benelux region and Italy into other European countries. We do not like to mention the country by name until we actually have line of sight on reimbursement. But the usual suspect, U.K., France, Germany, Austria, Switzerland. These are the usual suspect, but we will specifically discuss each country as we make significant headway on reimbursement for the OCS and the service.
Mm-hmm. Got it. We heard some European countries have cut their healthcare budgeting in favor of defense spending. How impactful is that, or how insulated is organ transplants?
Listen, I do not like to comment on geopolitical dynamic, but we all know the following is a fact. Organ transplant addresses a very, very expensive disease condition called end-stage organ failure that costs healthcare systems significant amount of dollars, even if you do not do anything, just leave them on medical therapy, is a very, very expensive proposition. So, I cannot comment on where the healthcare cutting took place, but I can only imagine, given the significant cost burden of end-stage organ failure, that that will be an area that will be protected. At least in the U.S., that has always been protected. So I am assuming European healthcare systems would react to the same disease condition in a similar fashion, but that is a hypothesis on my part.
Mm-hmm. Yep, fair enough. I guess, after Europe scales up, what is next in terms of geographies? APAC, LATAM, Middle East?
All of the above. Again, we like to walk before we run, before we sprint, before we fly. For us, there are several catalysts in front of us, like several catalysts in front of us. As we just discussed earlier, ENHANCE Part B for expanding at the heart market, DENOVO to launch or resurrect the lung market, Europe, again, going from a heart franchise in Europe for OCS to a heart, lung, and liver, standing up transplant logistics in Europe. So there is a lot in front of us before we expand. The next will be Middle East, LATAM, Far East, and Australia. We are extremely fortunate and humbled by the fact that TransMedics has a very, very robust and long pipeline that we are not going to run out of growth catalyst anytime soon.
All right. I mean, it sounds like there is a lot of positive updates. Should 2027 grow faster than 2026 conceptually?
I will start, and I will let Fernando comment from his perspective. I think we are a conservative company by nature. We are a growth company, but we are conservative by nature. We are going to issue guidance. We are going to assume in the first guidance release that we are going to be conservative, and we are going to focus on the organic growth drivers first, and then we will let the catalyst kind of up the operation and the execution of the growth catalyst speak for itself, and then we will update guidance as we go forward. But I will let Fernando comment on that.
Not much to add. I think Waleed said it the proper way, which is we will have the business be very focused on the base of what we have today, and then with the phasing of the implementation of the catalyst, hopefully we are going to be able to see an improved outlook for the year as we go through 2027. But we will start with the baseline as we have, and you see the guidance that is going to come when we release fourth quarter, very focused on that.
All right, great. Fernando, you joined TransMedics about two months ago. Still relatively early, but what has been your impression on the company so far versus before you joined, and what are some of the things you would be focused on for 2027?
No, absolutely. I would say, extremely excited, joining TransMedics, and even more excited today, because I know now more the catalyst, what we talked about, the opportunities we have. Coming from last week, I joined the forums, which really gives me the opportunity to speak to clinicians and with a lot of the users. Seeing firsthand, they are talking about the benefits of our technology, our full solution, really gives me a lot of hope that we have a lot of opportunities in the future. Young, to your question, what is going to be the focus for 2027? Very much focused on, number one, sustaining this growth, and making sure that we execute through the catalyst that we laid out during the earnings call.
As we mature the company more and more, driving operational rigor, so we have the capabilities of driving margin growth to the levels we want, as well as a strong cash generation through our day-to-day operations. Making this a sustainable company that is growing at a fast pace, but is also very focused on making sure that we have the right rigor, in making sure the company is long-term sustainable.
All right, excellent. I guess, maybe wanted to touch on kidney, one of the pipeline programs. That targets the 21,000 deceased kidneys, and 9,000 of which are unused. First in man expected in second half of 2027. What is the pathway for approval in terms of the trial sizing, data readouts?
Young, let me correct a couple of numbers you mentioned. Kidney targets 21,000 deceased kidney transplant procedures in the U.S., plus an additional 9,100 kidneys that are deceased donors that are unutilized due to extended ischemic time. We are talking about north of 30,000 deceased kidney transplant procedures a year in the U.S. alone, and a mirror image of that in Europe. The first patient we are targeting second half of 2027, not first half of 2027. As far as regulatory process, this is going to be a PMA product. It is going to require a randomized clinical trial in the U.S.
Because kidney disease and kidney transplant is a global issue, we are actually seriously considering launching an international program and a U.S. program in parallel rather than in series, just to capture the biggest portion of the market and deliver solutions to kidney transplant patients across the globe, all at the same time. The priority, of course, is launching the U.S. PMA process first, and then we will do an international program shortly thereafter, or they could run in parallel.
All right, got it. Will the kidney economics be materially different from the other organs?
We want to remind the audience that there are two kidneys per donor, so when you add the two kidneys, it will become, relatively speaking, at the same economics as the current heart, lung, and liver OCS.
Okay, got it.
The economic impact of increasing kidney transplant and improving post-transplant kidney function is humongous to CMS. We are talking hundreds of millions of dollars of cost savings and economic value to CMS. This was all published by HHS and the National Kidney Act that was published in October, summarizing the huge economical burden on CMS for end-stage renal disease for kidney transplantation.
Mm-hmm. On the OPO dynamics, the modernization initiative, seems like that was mostly in line with your expectations. It seems like a net positive for TransMedics. I guess I am wondering, if an OPO loses the DSA or gets decertified, how disruptive could that be within that region for organ transplants?
I think the CMS ruling was, I would say, in general, as expected. I would not call it positive or negative for TransMedics. TransMedics really was not impacted by those decisions. I think the decision that would really may impact TransMedics is the next decision CMS said that they would do, which is whether they allow a new entity to enter into What are the rules for new entities to become OPOs? As far as decertifying OPOs, I think CMS is being, or at least acting very responsible and trying to allow for a period of transition, trying to allow for a period of merger between OPOs. So, we think the disruption will be temporary, if any.
All right, great. Maybe one last one. There is a lot of positive updates. What do you see as the biggest risks to 2027?
I think the biggest risk always in my mind, and especially in 2027, is execution, our ability to execute. We laid out a strategy to launch all these catalysts for 2027. We executed. We are right at the starting gate. For us to capitalize on these catalysts, we have to execute. It is all in execution, and I have high degree of confidence in our team and in our ability to execute, just given the track record. But until we do it, we have to be laser-focused and vigilant on execution to make sure that we actually capitalize on these opportunities in front of us. But we are very, very bullish and excited about what 2027 can bring, not just for TransMedics, but to the field of organ transplantation in general.
All right. Excellent. Thank you very much.
Thank you, Young. Appreciate it.